Below are the financial statements of Pharmaron Beijing, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of CNY | 2024 | 2023 |
|---|---|---|
| Revenue | 12,275.78a | 11,538a |
| Cost of sales | -8,126.52a | -7,443.18a |
| Gross profit | 4,149.26a | 4,094.82a |
| Other income and gains | 884.52a | 374.01a |
| Other expenses | -67.76a | -37.9a |
| Selling and distribution expenses | -258.43a | -252.78a |
| Administrative expenses | -1,663.6a | -1,671.88a |
| Research and development costs | -469.26a | -448.28a |
| Impairment losses on financial and contract assets, net of reversal | -42.95a | -35.83a |
| Impairment losses of goodwill | -73.54a | 0a |
| Finance costs | -243.72a | -182.19a |
| Share of losses of associates | -123.26a | -2.08a |
| Profit before tax | 2,091.26a | 1,837.89a |
| Income tax expense | -377.1a | -256.11a |
| Profit for the year | 1,714.16a | 1,581.78a |
| Attributable to | — | — |
| Owners of the parent | 1,793.35a | 1,601.1a |
| Non-controlling interests | -79.19a | -19.32a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Pharmaron Beijing’s data sources below and access millions more through our Disclosure Search.